A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia
Sumithira Vasu, Jessica K. Altman, Geoffrey L. Uy, Martin S. Tallman, Ivana Gojo, Gerard Lozanski, Ute Burkard, Annika Osswald, Pamela James, Björn Rüter, William Blum
Abstract
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia *American Indian/Alaskan native and White. Data are n (%), unless otherwise stated. iHD: intensive high dose; pLD: palliative low dose; ECOG PS: Eastern Cooperative Oncology Group performance status; R/R AML: relapsed or refractory acute
Topics & Concepts
Monoclonal antibodyMyeloid leukemiaMedicineVirologyLeukemiaMonoclonalAntibodyMyeloidCancer researchImmunologyMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy researchChronic Lymphocytic Leukemia Research